|Articles|April 21, 2016
FDA's Breakthrough Designation is Working, Says Report
April 21, 2016.
Advertisement
The good news about FDA’s breakthrough drug initiative is that it actually appears to be accelerating clinical development of highly promising new therapies, according to recent analysis by Friends of Cancer Research (FOCR) .
Read Jill Wechsler's view in
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Shah Capital's Plan to Vote Against Novavax Board Nominees
2
Roche and C4 Therapeutics Expands Partnership with $1 Billion Collaboration Agreement
3
Shionogi Inc. Awarded $482 Million Contract with U.S. Government to Enhance National Preparedness for Drug-Resistant Bacterial Threats
4
Lipid Lowering with PCSK9 Inhibition: Long-Term Efficacy, Long-Standing Barriers
5